At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Doravirinedrug
Likely dose
Doravirine 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-1439 (Doravirine) in Subjects With Severe Renal Impairment
In Brief
A Phase 1 clinical trial evaluating Doravirine for Renal Impairment. Completed, enrolled 16 participants.
Detailed Summary
This study will evaluate the effect of severe renal impairment on the pharmacokinetics of doravirine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Impairment
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartJan 2016
Primary CompletionMay 2016
Study CompletionMay 2016
TodayJul 2026
First PostedDec 29, 2015
Enrollment StartJan 26, 2016
Primary CompletionMay 14, 2016
Study CompletionMay 25, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.5 years ago
Interventions
Doravirinedrug
Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally